Mizuho initiated coverage of Phreesia (PHR) with an Outperform rating and $36 price target Phreesia is a leader in patient intake management software for practitioners, the analyst tells investors in a research note. The firm likes the company’s ability to monetize its solutions via pharma digital marketing spend and is encouraged by the continued growth in its average healthcare services clients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHR: